Latest stories on BMY
Is BMY Undervalued? DCF Says Worth $159
GuruFocus63 · neutralanalyst
Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters
The Motley Fool74 · bullishproduct/pr
Bristol Myers Squibb: Bargain Buy or Value Trap?
The Motley Fool54 · neutralanalyst
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
MarketBeat74 · bullishproduct/pr
BioNTech and Bristol Myers Squibb Post Strong Phase 2 Pumitamig Data in Second‑Line Lung Cancer
TipRanks74 · bullishproduct/pr
Bristol Myers price target lowered to $78 from $82 at Piper Sandler
The Fly34 · bearishanalyst
Bristol Myers, SystImmune announce results from Phase 3 study of iza-bren
The Fly64 · neutralproduct/pr
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?
The Motley Fool57 · neutralanalyst
BioNTech, Bristol Myers announces data from Phase 2 ROSETTA Lung-107 trial
The Fly58 · neutralproduct/pr
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Morningstar38 · neutralproduct/pr
Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
Bloomberg38 · neutralproduct/pr
Bristol, Tempus AI partnering with Pathos AI to advance neurological treatments
Seeking Alpha63 · neutralproduct/pr
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors
MarketWatch42 · neutralgeneral
Bristol reports patient death in early trial of CAR-T therapy for multiple sclerosis
Seeking Alpha34 · bearishproduct/pr
BMY Stock Falls 2% After Patient Death In Early Multiple Sclerosis CAR T Trial
Stocktwits News34 · bearishgeneral
Bristol Myers tells Bloomberg aims to resume paused CAR-T trials in 2027
The Fly61 · neutralproduct/pr
Bristol Myers discloses death of CAR T patient in MS study
The Fly34 · bearishgeneral
Bristol Myers Reports CAR-T Death as Safety Concerns Mount
Bloomberg34 · bearishgeneral
Bristol Myers presents results from Phase 1 Breakfree-2 study
The Fly58 · neutralproduct/pr
Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals
MarketWatch64 · neutralproduct/pr